Revorf
Tokyo
About Revorf
Revorf is developing a testing business and a diagnostic drug development of support drug discovery and support business in relation to the neo-self theory, which is a new mechanism that explains the basis of autoimmune diseases. The methods are created by combining proprietary gene detection analysis technology, such as RNA, protein information analysis technology, data analysis, and artificial intelligence technology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $44.9M
- Last round: Series Unknown (Aug 2024)
- Website: revorf.jp
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Health Care, Medical
Canonical: https://fsome.com/organization/revorf-16647 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.